André Robidoux
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
Papers in
- Oncology 46
- Cancer Treatment and Pharmacology 18
- HER2/EGFR in Cancer Research 14
- Cancer Risks and Factors 6
-
- Breast Cancer Treatment Studies 37
- Cancer Genomics and Diagnostics 7
- Co-authors
- Norman Wolmark (39 shared papers)Joseph P. Costantino (19 shared papers)D. Lawrence Wickerham (7 shared papers)James N. Atkins (14 shared papers)Bernard Fisher (4 shared papers)Eleftherios P. Mamounas (31 shared papers)Victor G. Vogel (5 shared papers)Walter M. Cronin (4 shared papers)
- Journals
- Journal of Clinical Oncology (29 papers)Breast Cancer Research and Treatment (10 papers)The Lancet Oncology (6 papers)Clinical Breast Cancer (5 papers)Cancer Research (3 papers)
- Partner nations
- CanadaUnited StatesBelgium
In The Last Decade
André Robidoux
88 papers receiving 15.0k citations
André Robidoux's Hit Papers
Peers
Comparison fields: 5 of 136
- Cancer Research 7.2k
- Oncology 5.9k
- Pathology and Forensic Medicine 2.3k
- Genetics 3.8k
- Reproductive Medicine 535
Countries citing papers authored by André Robidoux
This map shows the geographic impact of André Robidoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Robidoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Robidoux more than expected).
Fields of papers citing papers by André Robidoux
This network shows the impact of papers produced by André Robidoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Robidoux. The network helps show where André Robidoux may publish in the future.
Co-authors
The 25 scholars most cited alongside André Robidoux, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 90 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Hit paper breakdown → | 1998 | 4367 |
| 2 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 Hit paper breakdown → | 2008 | 1367 |
| 3 | Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Hit paper breakdown → | 2010 | 1326 |
| 4 | Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Hit paper breakdown → | 2005 | 1003 |
| 5 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Hit paper breakdown → | 2011 | 889 |
| 6 | Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial Hit paper breakdown → | 2007 | 819 |
| 7 | Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 Hit paper breakdown → | 2006 | 744 |
| 8 | Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study Hit paper breakdown → | 2014 | 585 |
| 9 | 2010 | 494 | |
| 10 | 2005 | 412 | |
| 11 | 2012 | 331 | |
| 12 | 2019 | 289 | |
| 13 | 2013 | 273 | |
| 14 | 2011 | 259 | |
| 15 | 2008 | 253 | |
| 16 | 2014 | 146 | |
| 17 | 2012 | 137 | |
| 18 | 2014 | 122 | |
| 19 | 2005 | 118 | |
| 20 | 2007 | 109 |
About André Robidoux
André Robidoux is a scholar working on Oncology, Cancer Research, Genetics, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 90 papers that have together received 15.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (37 papers), Cancer Treatment and Pharmacology (18 papers), HER2/EGFR in Cancer Research (14 papers), BRCA gene mutations in cancer (8 papers), Cancer Genomics and Diagnostics (7 papers), Advanced Breast Cancer Therapies (7 papers), Estrogen and related hormone effects (6 papers) and Cancer Risks and Factors (6 papers). The work is most often cited by research in Cancer Research (7.2k citations), Oncology (5.9k citations), Pathology and Forensic Medicine (2.3k citations), Genetics (3.8k citations) and Reproductive Medicine (535 citations). André Robidoux has collaborated with scholars based in Canada, United States and Belgium. Frequent co-authors include Norman Wolmark, Joseph P. Costantino, D. Lawrence Wickerham, James N. Atkins, Bernard Fisher, Eleftherios P. Mamounas, Victor G. Vogel, Walter M. Cronin, Leslie G. Ford and Maureen Kavanah. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, The Lancet Oncology, Clinical Breast Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.